Are We Overtreating Early Rheumatoid Arthritis in the Biologic Era Abstract The introduction of biologic disease modifying antirheumatic drugs has fundamentally reshaped the management of rheumatoid arthritis over the past two decades. These agents, in combination with conventional synthetic therapies and treat to target strategies, have significantly
